Bli medlem
Bli medlem

Du är här


aap Implantate AG: Attractive divestment of Contract Manufacturing subsidiary and Trauma/LOQTEQ® growth of 47% give aap a good start in 2014

aap Implantate AG / Attractive divestment of Contract Manufacturing subsidiary
and Trauma/LOQTEQ®growth of 47% give aap a good start in 2014 . Processed and
transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely
responsible for the content of this announcement.
In the first three months of the financial year 2014,aap
sales totalled EUR 7.1 million (previous year: EUR 10.4 million). First
quarter 2014 sales included only two months of EMCM sales; the divestment was
effective as of February 28th. On a like for-like-basis, first quarter 2014
sales (without project sales of EUR 1.5 million in Q1 2013) from continued
operations grew 33% from EUR 4.6 million to EUR 6.1 million.

Group (Total, incl. EMCM for two months of 2014)
|In EUR million Q1/2014 Q1/2013 Change |
|Sales 7.1 10.4 -31 % |
|EBITDA 0.1 3.1 -96 % |
|EBIT -0.4 2.3 k. A. |

Continued operations (without projects)
|In EUR million Q1/2014 Q1/2013 Change |
|Sales 6,1 4.6 33 % |
|EBITDA 0.1 -1.1 >100 % |
| |
| -1.1 |
|EBIT -0.4 -1.6 75 %. |

In the first quarter of 2014 the Company continued to deliver on its strategic
objectives, as illustrated by the following highlights:

* Strong sales growth of the Trauma/LOQTEQ® product portfolio: +47% (from EUR
1.5 million to EUR 2.2 million); LOQTEQ® growth stand alone of +175%
* Divestment of the non core contract manufacturing subsidiary EMCM for EUR
18 million
* Receiving a US patent on silver coating

The ongoing positive development of the Trauma/ LOQTEQ® portfolio was
supported by:

- Sale driver were: Russia, Turkey, Italy, Spain, Czech Republic and
- Filing of registration documents for new LOQTEQ® products in
countries such as Russia, Iran, Iraq
- Zero reports of any cold welding events in the first quarter

The Company's R&D activities remain on track, including the further extension
of the LOQTEQ® portfolio with one new system in the first quarter of 2014. In
February, the Company announced that it was granted a US patent covering its
silver coating technology. This promising technology has the potential to
prevent infections, one of the fundamental challenges in treating trauma
s development activities with Chinese partner eontech Co. Ltd. for resorbable
magnesium technology is in the advanced stage of selection of the active
material and preferred coating.

2014 and 2015 Outlook
As reported earlier, the Company has evaluated strategic options for its
Biomaterial/bone cement subsidiaryaap
Biomaterials GmbH in Dieburg. After a thorough review, the Company believes
that the value of bothaap
Implantate AG andaap
Biomaterials GmbH may benefit from a spin off ofaap
Biomaterials GmbH; with the timing of such a transaction being an important
consideration. The management board has appointed an experienced
merger&acquisition (M&A) company to assist in the execution of this project.

The Company expects sales for the second quarter to be between EUR 7.6 million
and EUR 8.2 million (Second quarter 2013 (excl. EMCM): EUR 6.6 million). The
EBITDA forecast for the second quarter amounts between EUR 1.0 million and
EUR 1.5 million (Second quarter 2013 (excl. EMCM): EUR 0.2 million).

The management board is reaffirming the sales and EBITDA outlook for the full
year of 2014: Sales of EUR 35 million and an EBITDA of between EUR 5 million
and EUR 6 million.

Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All
German stock markets -

Implantate AG
is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that
are used in orthopedic procedures. The Company's products, which include a
full line of plating systems, cannulated screws and bone cement products, are
primarily used in the orthopedic specialty areas of trauma and spine repair.
The Company's products are sold through its direct sales force, distribution
partners and license agreements with OEM partners.aap
's stock is listed in the Prime Standard segment of the Frankfurt Stock
Exchange. For more information, please visit, or download the
Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements of aap to
be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or

For inquiries please contact:aap
Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin,

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap

Press Release aap 15.5.2014


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.